Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Defense
Mayo Clinic Center for Individualized Medicine Mayo Clinic Center for Regenerative Biotherapeutics Mayo Clinic Comprehensive Cancer Center Henry J Predolin Foundation
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference73 articles.
1. Sakemura R, Cox MJ, Hefazi M, Siegler EL, Kenderian SS. Resistance to cart cell therapy: Lessons learned from the treatment of hematological malignancies. Leuk lymphoma. 2021;62:2052–63.
2. June CH, O’Connor RS, Kawalekar OU, Ghassemi S, Milone MC. Car T cell immunotherapy for human cancer. Science. 2018;359:1361–5.
3. Benmebarek M-R, Karches C, Cadilha B, Lesch S, Endres S, Kobold S. Killing mechanisms of chimeric antigen receptor (CAR) T cells. Int J Mol Sci. 2019;20:1283.
4. Center for Drug Evaluation and Research. FDA D.I.S.C.O. burst: Approval of ABECMA (idacabtagene vicleucel) [Internet]. U.S. Food and Drug Administration. FDA; 2021 [cited 2021Oct31]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-disco-burst-edition-fda-approval-abecma-idecabtagene-vicleucel-first-fda-approved-cell-based
5. Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and Perspectives. Sci Adv. 2023;9:eadf3700.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献